A Study to Evaluate Safety, Tolerability, and Immunogenicity of V350A and V350B in Healthy Participants (V350-001).
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Trial to Evaluate the Safety, Tolerability, and Immunogenicity of V350A and V350B in Healthy Participants.
Merck Sharp & Dohme LLC
250 participants
Dec 5, 2024
INTERVENTIONAL
Conditions
Summary
Epstein Barr virus (EBV) is a virus which can cause infectious mononucleosis and is associated with certain kinds of cancer and multiple sclerosis. Researchers are looking for new ways to prevent disease related to EBV and have developed a new study vaccine (V350A and V350B). The main goal of this study is to learn about the safety and tolerability of V350A and V350B in healthy adults.
Eligibility
Inclusion Criteria2
- Is in good health before randomization.
- Has a body mass index between 18 and 38 kg/m\^2, inclusive, for adults 18-30; has a body mass index between 15 and 38 kg/m\^2, inclusive, for adolescents 12-17.
Exclusion Criteria2
- Has a confirmed or suspected case of infectious mononucleosis within 12 months prior to enrollment.
- Has any immunosuppressive medical condition or receive any immunosuppressive therapy.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Vaccination administered via intramuscular injection
Vaccination administered via intramuscular injection
Vaccination administered via intramuscular injection
Locations(9)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06655324